Member Info for Matador78

Seriously Darren, you don't need to comment on every post. Can you not tell when someone is trying to have a conversation?

Is it not obvious to you that people would rather you stop posting for a while?

Weve tried to do it politely but it seems beyond you.

Why ask?

Range of Plant based protein drinks on route

https://www.internwise.co.uk/events/details/32675-MYO-Plant-Nutrition-Sales-Internship/

This board today. It reminds me of the end of an episode of Poirot.

https://www.itv.com/news/2020-02-10/british-american-tobacco-looking-into-cannabis-vape-flavours/

“It is only right for us to evaluate the science in that space and the regulatory frameworks that exist,” he said.

“At the minute it is very much a watching brief of what is happening in that area but we are monitoring it closely.”

https://beta.companieshouse.gov.uk/officers/HHBUrOPfmtfQdtWjQ3-MFDSw5zY/appointments

For a completely different company

https://harmony.one/team/

Did you read that link before you posted it Darren?

Do you know who Stephen Tse is?

Why the trend on SP when OSI seems to have such good news flow?

Unless it includes removing the battery from your phone I'm not interested

Shush now ego.

Keep an eye on the buys theyll be coming soon.

And who was it's author?

Accurate, aside from I don't see any real intelligence in the posts here.

just guile.

A shilling or two

There will be more buying today.

Ting Tong signing out.

https://www.healtheuropa.eu/history-made-with-first-ever-israeli-cannabis-import-into-the-uk/97132/

FastForward Innovations Ltd, the AIM quoted company focusing on making investments in fast growing and industry leading businesses, notes the following announcement released on 18 February 2020 concerning investee company EMMAC Life Sciences Limited ("EMMAC"). FastForward has a current equity interest totaling 2.4% in the stock of EMMAC.



The announcement is set out below without material changes or adjustments.



18 February 2020, London. EMMAC Life Sciences Group, Europe's leading independent cannabis company, is pleased to announce it has successfully exported 400 kilograms of medical cannabis to Israel, to the Bazelet Group, the largest medical cannabis company in Israel. The 400 kilograms of dried flower, the largest amount of product imported into Israel to date, was shipped from EMMAC's cultivation facility, Terra Verde, in Portugal, making EMMAC the first independent European company to export medical cannabis to Israel.



Commenting on this milestone, Antonio Costanzo, CEO of EMMAC, said: "EMMAC is very pleased to be the first independent European company to export medical cannabis to Israel through our partnership with Bazelet, supplying the highest-quality product to meet growing patient demand for medical cannabis."



The Bazelet Group is the largest Good Manufacturing Practices ('GMP') processor of medical cannabis in Israel, serving monthly, thousands of patients. Bazelet has years of experience in the pharmaceutical cannabis industry and is constantly developing new products and technologies. Bazelet has filed so far 33 provisional patent applications, of which 12 are in the Patent Cooperation Treaty ('PCT') stage.



Meir Ariel, CEO of the Bazelet Group, said: "We are very pleased to be working with EMMAC. We believe both The Bazelet Group and EMMAC share the same commitment to providing patients with premium, high quality medical cannabis and we look to strengthening our relationship in the years to come."



Commenting on EMMAC's wider strategy, Antonio Costanzo said: "2019 was extremely busy as we executed our strategy to strengthen our position in the European medical cannabis and wellness markets. We are particularly pleased we are now establishing ourselves in the mature Israeli medical cannabis market. Israel represents an important market for us and we look forward to building on this agreement by exporting more product to Israel over the course of 2020 and beyond."

This is where Socati sees an opportunity to differentiate itself, according to Mark Elfenbein, the company’s chief revenue officer, by dialing formulations in to exact cannabinoid ratios to provide a consistent and efficacious user experience.

“One of the unique things about our technology is that we are able to separate minor cannabinoids and then effectively reproduce the product to spec,” he said. “If there is a customer requiring a certain amount of minor cannabinoids, either in total or specifically, we can do that.”

Even more than with CBD, greater research and clinical trial is needed to better understand the range of other minor cannabinoids that can be derived from cannabis, with each playing a different role within the endocannabinoid system. Some studies suggest that CBG (cannabigerol) offers antibacterial and antispasmodic effects, while CBN (cannabinol) can work as a natural aid for sleep, which is among the main points of entry for medicinal or semi-medicinal cannabis use, according to New Frontier Data. Further down the line, there’s also THC-V, which has shown promise as an appetite suppressant in tests using rats, and THC-A, which has purported neuroprotective and anti-inflammatory effects. Adding another layer of complexity for formulators, those effects can sometimes be enhanced by the presence of other cannabinoids, including THC.

https://www.bevnet.com/news/2020/hemp-horizons-socatis-private-label-targets-minor-cannabinoids

You're Welcome

You're extra special Wadnob

Portage or NASDAQ or spiteful sellers.

or any other suppositions.

It's about value for money from proper investors.

FACT

A tincture for bad investment decisions?

or enjoying classical music?